Imfinzi (durvalumab) - AstraZeneca
relatlimab (BMS-986016) - BMS
Yervoy (ipilimumab) - BMS
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Keytruda (pembrolizumab) - Merck (MSD)
http://www.ncbi.nlm.nih.gov/pubmed/42746766
 
Connor Frey; Mahyar Etminan; Sonia N Yeung
 
Sep 17, 2026
 
Prev Next